Research graph
References from Liso-cel delivers: is the debate over for 3L FL?. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1182/blood.2026034327 · 2026 · Admitted local publication
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study
10.1038/s41591-024-02986-9 · 2024 · External reference
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
10.1016/s1470-2045(22)00335-7 · 2022 · External reference
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study
10.1016/s2352-3026(24)00166-2 · 2024 · External reference
Five-year follow-up analysis of ZUMA-5: axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma
10.1200/jco-25-00668 · 2025 · External reference
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update
10.1182/blood.2023021567 · 2024 · External reference
Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): phase 2 ELARA 5-year update [abstract]
10.1182/blood-2025-468 · 2025 · External reference
A comparison of 3-year follow-up of ZUMA-5 (axicabtagene ciloleucel) with SCHOLAR-5 in relapsed/refractory follicular lymphoma
10.1016/j.clml.2024.01.011 · 2024 · External reference
Unresolved reference
External reference
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial
10.1016/s0140-6736(25)02360-8 · 2026 · External reference
